Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Jun 4, 2026

•

3 min read

Biotech & Pharma Updates | June 4, 2026

🧬 Innovent Biologics' (arcotatug tavatecan) hits Ph3 win in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma, Alnylam Pharmaceuticals, Inceptive Nucleics partner on AI-driven siRNA drug discovery, $30M upfront, up to $2B total, Parabilis plans up to $476M IPO, advancing peptide drug zolucatetide for desmoid tumors

Christian Cuchapin, +1

Jun 3, 2026

•

3 min read

Biotech & Pharma Updates | June 3, 2026

🧬 Legend Biotech's (LB2501) achieves 100% response rate in Ph1 non-Hodgkin lymphoma in vivo CAR T study, NewLimit raises $435M Series C, advancing epigenetic reprogramming medicine toward human trials, Eli Lilly, Ascidian Therapeutics partner on RNA exon editing for kidney diseases, up to $1.9B

Christian Cuchapin, +1

Jun 2, 2026

•

4 min read

Biotech & Pharma Updates | June 2, 2026

🧬 Moderna, Merck & Co.'s (intismeran autogene) plus Keytruda shows 49% recurrence risk reduction in Ph2b high-risk melanoma, Bristol Myers Squibb's (izalontamab brengitecan) Ph3 trial shows 40% reduced death risk in triple-negative breast cancer, Rallybio merges with Avenzo Therapeutics in reverse merger, backed by $215M private placement

Christian Cuchapin, +1

Jun 1, 2026

•

4 min read

Biotech & Pharma Updates | June 1, 2026

🧬 Eli Lilly's Kelonia Therapeutics' (KLN-1010) shows 100% response rate in Ph1 relapsed or refractory multiple myeloma trial, Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 metastatic pancreatic cancer with KRAS mutation, Gilead's TUB-040 (NaPi2b-targeting ADC) shows 61% tumor response in Ph1 platinum-resistant ovarian cancer trial

Christian Cuchapin, +1

Long Form Content

The Most Skeptical Buyer - Selling To Scientists

May 30, 2026

•

8 min read

The Most Skeptical Buyer - Selling To Scientists

Selling to Scientists & Technical Industries

Anis Fahandej-Sadi

May 29, 2026

•

3 min read

Biotech & Pharma Updates | May 29, 2026

🧬 Pfizer, Innovent Biologics strike $10B cancer deal covering 12 ADC and multispecific antibody programs, $650M upfront, AstraZeneca's Imfinzi (durvalumab) wins FDA approval for BCG-naïve high-risk non-muscle-invasive bladder cancer after Ph3 win, Replimune resubmits RP1 melanoma BLA for third time following major FDA leadership shakeup

Christian Cuchapin, +1

May 28, 2026

•

3 min read

Biotech & Pharma Updates | May 28, 2026

🧬 GSK, Ionis Pharmaceuticals' (bepirovirsen) achieves Ph3 functional cure in nearly 20% of chronic hepatitis B patients, AbbVie's Decnupaz wins FDA approval for blastic plasmacytoid dendritic cell neoplasm, targeting CD123 in Ph1/2, Secretome Therapeutics raises $30M Series A to advance cardiac cell therapies pipeline

Christian Cuchapin, +1

May 27, 2026

•

3 min read

Biotech & Pharma Updates | May 27, 2026

🧬 Outlook Therapeutics' Lytenava (bevacizumab) gains FDA appeal win for wet age-related macular degeneration, AstraZeneca's (camizestrant) FDA review delayed after advisory committee rejects Ph3 data for HR-positive breast cancer, Astellas unveils five-year growth strategy to offset Xtandi patent expiry through pipeline acquisitions

Christian Cuchapin, +1

Biotech & Pharma Updates | May 21 - 26, 2026

May 26, 2026

•

3 min read

Biotech & Pharma Updates | May 21 - 26, 2026

🧬 Eli Lilly to acquire Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8B to build infectious disease pipeline

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | June 4, 2026

Biotech & Pharma Updates | June 3, 2026

Biotech & Pharma Updates | June 2, 2026

Biotech & Pharma Updates | June 1, 2026

The Most Skeptical Buyer - Selling To Scientists

Biotech & Pharma Updates | May 29, 2026

Biotech & Pharma Updates | May 28, 2026

Biotech & Pharma Updates | May 27, 2026

Biotech & Pharma Updates | May 21 - 26, 2026

TLDR Biotech

FAQ

Media Partners